NEW YORK (GenomeWeb News) – Metabolite-based diagnostic firm Matrix-Bio announced today it has signed an exclusive agreement with the Purdue Research Foundation to potentially develop cancer diagnostic tests based on Purdue University's technologies.
Matrix-Bio is optioning metabolite biomarker technology and eight patent applications as part of the deal in order to assess the commercial potential of tests based on the technologies. The technologies include metabolite biomarkers for the detection of esophageal, liver, pancreatic, and colon cancer; biomarkers for identifying liver cancer in hepatitis C patients; and biomarkers for predicting pre-operative chemotherapy effectiveness for breast cancer treatment.
The deal is for one year with an option to extend it. No further details were disclosed.
Today's deal builds on a master licensing agreement between the Fort Wayne, Ind.-based company and Purdue Research Foundation for breast cancer biomarkers and metabolite profiling technology that was developed by the company's founder and CSO, Dan Raftery, while he was at Purdue. He is now director of the Northwest Metabolomics Research Center at the University of Washington and a member of the Fred Hutchinson Cancer Research Center.
The agreement, Matrix-Bio CEO Eric Beier, said in a statement, "will enable the company to significantly expand its pipeline of detection and monitoring tests, further advancing the company's leadership in metabolomics-based cancer diagnostic technologies."
Its technology platform combines mass spectrometry and nuclear magnetic resonance to identify biomarkers that may be associated with early stage breast cancer and recurrence post-therapy.
In April, Matrix-Bio reached a deal with Quest Diagnostics for the use of metabolomic biomarkers in developing a breast cancer recurrence test.